Free Trial
→ Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (From Colonial Metals) (Ad) Free NBIX Stock Alerts

Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences logo
$125.51 -1.50 (-1.18%)
(As of 11/13/2024 ET)
Compare

Neurocrine Biosciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 24 Analyst Ratings
Sell
0
Hold
5
Buy
19

Based on 24 Wall Street analysts who have issued ratings for Neurocrine Biosciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 5 have given a hold rating, 18 have given a buy rating, and 1 has given a strong buy rating for NBIX.

Consensus Price Target

$163.91
30.60% Upside
According to the 24 analysts' twelve-month price targets for Neurocrine Biosciences, the average price target is $163.91. The highest price target for NBIX is $219.00, while the lowest price target for NBIX is $114.00. The average price target represents a forecasted upside of 30.60% from the current price of $125.51.

NBIX Analyst Ratings Over Time

TypeCurrent Forecast
11/15/23 to 11/14/24		1 Month Ago
10/16/23 to 10/15/24		3 Months Ago
8/17/23 to 8/16/24		1 Year Ago
11/15/22 to 11/15/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
18 Buy rating(s)
18 Buy rating(s)
16 Buy rating(s)
16 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
6 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$163.91$164.52$158.68$131.46
Forecasted Upside30.60% Upside40.21% Upside9.43% Upside18.74% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

NBIX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NBIX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Neurocrine Biosciences Stock vs. The Competition

TypeNeurocrine BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
2.83
2.80
2.50
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside30.60% Upside26,278.29% Upside8.03% Upside
News Sentiment Rating
Positive News

See Recent NBIX News
Positive News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/11/2024Needham & Company LLC
2 of 5 stars		 Reiterated RatingHold
11/1/2024HC Wainwright
2 of 5 stars		 Reiterated RatingBuy ➝ Buy$190.00 ➝ $190.00+57.98%
10/17/2024BMO Capital Markets
4 of 5 stars		 Lower TargetMarket Perform ➝ Market Perform$128.00 ➝ $114.00-4.11%
10/10/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		D. Brill
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOutperform$155.00+38.86%
10/4/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetSector Perform ➝ Sector Perform$136.00 ➝ $133.00+18.04%
9/16/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOverweight ➝ Overweight$155.00 ➝ $155.00+26.85%
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

Get Your Free Gold Guide
9/9/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$180.00 ➝ $160.00+31.77%
8/29/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Overweight$131.00 ➝ $159.00+28.47%
8/19/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$177.00 ➝ $189.00+29.88%
8/7/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$173.00 ➝ $181.00+24.07%
8/2/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$170.00 ➝ $180.00+18.22%
8/2/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$216.00 ➝ $219.00+44.21%
8/2/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral ➝ Neutral$150.00 ➝ $158.00+4.04%
8/2/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$157.00 ➝ $180.00+15.96%
7/12/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$160.00 ➝ $170.00+14.76%
5/29/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform ➝ Outperform$152.00 ➝ $152.00+8.20%
5/28/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$174.00 ➝ $193.00+38.45%
5/14/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform$175.00+28.53%
5/2/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$154.00 ➝ $164.00+16.41%
4/24/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeEqual Weight ➝ Overweight$140.00 ➝ $170.00+21.35%
2/8/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral ➝ Neutral$116.00 ➝ $140.00+4.38%
1/25/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$134.00 ➝ $153.00+9.20%
12/18/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$141.00 ➝ $144.00+19.73%
12/12/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$136.00+14.76%
10/8/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$137.00 ➝ $143.00+25.52%
10/6/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating		M. Goodman
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target$125.00 ➝ $135.00+17.09%
7/24/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeMarket Perform ➝ Outperform$115.00 ➝ $125.00+26.53%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:23 AM ET.


NBIX Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Neurocrine Biosciences is $163.91, with a high forecast of $219.00 and a low forecast of $114.00.

24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 5 hold ratings, 18 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NBIX shares.

According to analysts, Neurocrine Biosciences's stock has a predicted upside of 30.60% based on their 12-month stock forecasts.

Over the previous 90 days, Neurocrine Biosciences's stock had 1 upgrade by analysts.

Neurocrine Biosciences has been rated by research analysts at Barclays, BMO Capital Markets, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group, Needham & Company LLC, Piper Sandler, Raymond James, and Royal Bank of Canada in the past 90 days.

Analysts like Neurocrine Biosciences more than other "medical" companies. The consensus rating score for Neurocrine Biosciences is 2.83 while the average consensus rating score for "medical" companies is 2.80. Learn more on how NBIX compares to other companies.

Related Companies
Today's Ratings
Top Rated Stocks
More Ratings Tools

This page (NASDAQ:NBIX) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners
Blackrock’s Sending THIS Crypto Higher on Purpose
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...
Crypto 101 Media | Sponsored
What are you hiding Elon?? (Tesla’s secret 69% dividend)
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Bill Gates’s Next Big AI Bet: Stargate
In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...
Brownstone Research | Sponsored
[625,000% Gain] – Are You Ready for the Next Altcoin Boom?
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...
Crypto Swap Profits | Sponsored
Crypto’s next big bull run?
Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...
Weiss Ratings | Sponsored
War on Elon Escalates…
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...
Porter & Company | Sponsored
⭕ [URGENT] Buy Alert just triggered
My absolute favorite stock just hit a critical "buy now" trigger price.
Behind the Markets | Sponsored
New post-election stock warning from Wall Street
If you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...
Chaikin Analytics | Sponsored